BMS-986369
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory T-cell Lymphomas
Conditions
Relapsed or Refractory T-cell Lymphomas
Trial Timeline
Nov 20, 2023 → Oct 10, 2030
NCT ID
NCT06035497About BMS-986369
BMS-986369 is a phase 1/2 stage product being developed by Bristol Myers Squibb for Relapsed or Refractory T-cell Lymphomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06035497. Target conditions include Relapsed or Refractory T-cell Lymphomas.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory T-cell Lymphomas were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06035497 | Phase 1/2 | Recruiting |
| NCT05567510 | Phase 1 | Completed |
| NCT05350800 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory T-cell Lymphomas